Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48.
Article
PubMed
Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Article
PubMed
Google Scholar
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, et al. Pancreatic cancer Nat Rev Dis Primers. 2016;2:16022.
Article
PubMed
Google Scholar
Motoi F, Unno M. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Jpn J Clin Oncol. 2020;50(5):483–9.
Article
PubMed
Google Scholar
Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of Pancreatic Cancer. Cancer J. 2015;21(3):188–93.
Article
CAS
PubMed Central
PubMed
Google Scholar
Wang Y, Zhong X, Zhou L, Lu J, Jiang B, Liu C, Guo J. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Front Oncol. 2020;10:1466.
Article
PubMed Central
PubMed
Google Scholar
Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1):130.
Article
PubMed Central
PubMed
Google Scholar
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6.
Article
CAS
PubMed Central
PubMed
Google Scholar
Fischer CG, Wood LD. From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions. J Pathol. 2018;246(4):395–404.
Article
PubMed Central
PubMed
Google Scholar
Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, Guerrero PA, Huang YQ, Zhao J, Kamyabi N, et al. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. Clin Cancer Res. 2019;25(7):2194–205.
Article
CAS
PubMed
Google Scholar
Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, Szabo C, Zhang LZ, Eckloff BW, Petersen GM, et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology. 2013;145(5):1098-+.
Article
CAS
PubMed
Google Scholar
Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, et al. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol. 2020;38(13):1442-+.
Article
CAS
PubMed
Google Scholar
Andricovich J, Perkail S, Kai Y, Casasanta N, Peng WQ, Tzatsos A. Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors. Cancer Cell. 2018;33(3):512-+.
Article
CAS
PubMed Central
PubMed
Google Scholar
Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22(5):497–505.
Article
CAS
PubMed Central
PubMed
Google Scholar
Li SQ, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18(12):767–77.
Article
CAS
PubMed
Google Scholar
Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2012;22(3):318–30.
Article
CAS
PubMed Central
PubMed
Google Scholar
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–8.
Article
CAS
PubMed
Google Scholar
Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sanchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015;21(10):1163–71.
Article
CAS
PubMed Central
PubMed
Google Scholar
Wang L, Zhao ZB, Ozark PA, Fantini D, Marshall SA, Rendleman EJ, Cozzolino KA, Louis N, He XY, Morgan MA, et al. Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy. Nat Med. 2018;24(6):758-+.
Article
CAS
PubMed Central
PubMed
Google Scholar
Wang J, Chen C, Li HF, Jiang XL, Zhang L. Investigating key genes associated with ovarian cancer by integrating affinity propagation clustering and mutual information network analysis. Eur Rev Med Pharmacol Sci. 2016;20(12):2532–40.
CAS
PubMed
Google Scholar
Calverley DC, Phang TL, Choudhury QG, Gao BF, Oton AB, Weyant MJ, Geraci MW. Significant Downregulation of Platelet Gene Expression in Metastatic Lung Cancer. Cts-Clin Transl Sci. 2010;3(5):227–32.
Article
CAS
Google Scholar
Dampier CH, Devall M, Jennelle LT, Diez-Obrero V, Plummer SJ, Moreno V, Casey G. Oncogenic Features in Histologically Normal Mucosa: Novel Insights Into Field Effect From a Mega-Analysis of Colorectal Transcriptomes. Clin Transl Gastroenterol. 2020;11(7):e00210.
Article
PubMed Central
PubMed
Google Scholar
Muraro MJ, Dharmadhikari G, Grun D, Groen N, Dielen T, Jansen E, van Gurp L, Engelse MA, Carlotti F, de Koning EJ, et al. A Single-Cell Transcriptome Atlas of the Human Pancreas. Cell Syst. 2016;3(4):385-394 e383.
Article
CAS
PubMed Central
PubMed
Google Scholar
Schlesinger Y, Yosefov-Levi O, Kolodkin-Gal D, Granit RZ, Peters L, Kalifa R, Xia L, Nasereddin A, Shiff I, Amran O, et al. Single-cell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells’ heterogeneity. Nat Commun. 2020;11(1):4516.
Article
CAS
PubMed Central
PubMed
Google Scholar
Lin W, Noel P, Borazanci EH, Lee J, Amini A, Han IW, Heo JS, Jameson GS, Fraser C, Steinbach M, et al. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med. 2020;12(1):80.
Article
CAS
PubMed Central
PubMed
Google Scholar
Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495–502.
Article
CAS
PubMed Central
PubMed
Google Scholar
Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–20.
Article
CAS
PubMed Central
PubMed
Google Scholar
Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30(4):523–30.
Article
PubMed
Google Scholar
Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79.
Article
CAS
PubMed
Google Scholar
Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther. 2011;12(3):165–8.
Article
CAS
PubMed
Google Scholar
Jiang Y, Sohal DPS. Pancreatic Adenocarcinoma Management. JCO Oncol Pract. 2022;9(22):OP2200328.
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6(6):369–76.
Article
CAS
PubMed
Google Scholar
Picozzi VJ, Abrams RA, Decker PA, Traverso W, O’Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011;22(2):348–54.
Article
CAS
PubMed
Google Scholar
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.
Article
PubMed Central
PubMed
Google Scholar
Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy Front. Oncol. 2021;11:688377.
Google Scholar
Qadir MMF, Alvarez-Cubela S, Klein D, van Dijk J, Muniz-Anquela R, Moreno-Hernandez YB, Lanzoni G, Sadiq S, Navarro-Rubio B, Garcia MT, et al. Single-cell resolution analysis of the human pancreatic ductal progenitor cell niche. Proc Natl Acad Sci U S A. 2020;117(20):10876–87.
Article
CAS
PubMed Central
PubMed
Google Scholar
Wang YJ, Schug J, Won KJ, Liu C, Naji A, Avrahami D, Golson ML, Kaestner KH. Single-Cell Transcriptomics of the Human Endocrine Pancreas. Diabetes. 2016;65(10):3028–38.
Article
CAS
PubMed Central
PubMed
Google Scholar
Jahan R, Ganguly K, Smith LM, Atri P, Carmicheal J, Sheinin Y, Rachagani S, Natarajan G, Brand RE, Macha MA, et al. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. EBioMedicine. 2019;42:375–85.
Article
PubMed Central
PubMed
Google Scholar
Guppy NJ, El-Bahrawy ME, Kocher HM, Fritsch K, Qureshi YA, Poulsom R, Jeffery RE, Wright NA, Otto WR, Alison MR. Trefoil factor family peptides in normal and diseased human pancreas. Pancreas. 2012;41(6):888–96.
Article
CAS
PubMed
Google Scholar
Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H, Toma H, Takahata S, Sato N, Nagai E, et al. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol. 2007;213(3):275–82.
Article
CAS
PubMed
Google Scholar
Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Buchler MW, Reiter RE, Hines OJ. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31(2):119–25.
Article
CAS
PubMed
Google Scholar
Hosokawa M, Kashiwaya K, Eguchi H, Ohigashi H, Ishikawa O, Furihata M, Shinomura Y, Imai K, Nakamura Y, Nakagawa H. Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Sci. 2008;99(8):1626–32.
Article
CAS
PubMed
Google Scholar
Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74.
Article
CAS
PubMed
Google Scholar
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84.
Article
CAS
PubMed
Google Scholar
Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ, Arning M, Schalhorn A, Possinger K, Fink U. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol. 2000;11(11):1399–403.
Article
CAS
PubMed
Google Scholar
Wang S, Huang S, Sun YL: Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. Biomed Res Int 2017, 2017.
Luu T. Epithelial-Mesenchymal Transition and Its Regulation Mechanisms in Pancreatic Cancer Front. Oncol. 2021;11:646399.
Google Scholar
Jennings RE, Berry AA, Strutt JP, Gerrard DT, Hanley NA. Human pancreas development. Development. 2015;142(18):3126–37.
Article
CAS
PubMed
Google Scholar
Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119(6):1429–37.
Article
CAS
PubMed Central
PubMed
Google Scholar
Maddipati R, Norgard RJ, Baslan T, Rathi KS, Zhang A, Saeid A, Higashihara T, Wu F, Kumar A, Annamalai V, et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 2021;12(2):542-61.
Whitfield JR, Soucek L. The long journey to bring a Myc inhibitor to the clinic. J Cell Biol. 2021;220(8):e202103090.
Article
CAS
PubMed Central
PubMed
Google Scholar
Carabet LA, Rennie PS, Cherkasov A. Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches. Int J Mol Sci. 2019;20(1):120.
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.
Article
CAS
PubMed
Google Scholar
Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastro Hepat. 2012;9(8):435–44.
Article
CAS
Google Scholar
Kanno A, Masamune A, Hanada K, Kikuyama M, Kitano M. Advances in Early Detection of Pancreatic Cancer. Diagnostics (Basel). 2019;9(1):18.
Article
Google Scholar
Franck C, Muller C, Rosania R, Croner RS, Pech M, Venerito M. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers (Basel). 2020;12(7):1955.
Article
CAS
Google Scholar
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–20.
Article
CAS
PubMed
Google Scholar
Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18(7):1338.
Article
PubMed Central
Google Scholar
Lemmens VEPP, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JWW, de Hingh IHJT. Improving outcome for patients with pancreatic cancer through centralization. Brit J Surg. 2011;98(10):1455–62.
Article
CAS
PubMed
Google Scholar
Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Postgrad Med J. 2008;84(995):478–97.
Article
CAS
PubMed
Google Scholar
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol. 2009;27(33):5513–8.
Article
CAS
PubMed
Google Scholar
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72.
Article
CAS
PubMed
Google Scholar
Zhang WH, Wang WQ, Han X, Gao HL, Li TJ, Xu SS, Li S, Xu HX, Li H, Ye LY, et al. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Comput Struct Biotechnol J. 2020;18:3606–14.
Article
CAS
PubMed Central
PubMed
Google Scholar
Sinclair K, Dudley E. Metabolomics and Biomarker Discovery. Adv Exp Med Biol. 2019;1140:613–33.
Article
CAS
PubMed
Google Scholar
Moutinho-Ribeiro P, Macedo G, Melo SA. Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Front Endocrinol. 2019;9:779.
Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ. The Clinical Utility of CA 19–9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. Curr Mol Med. 2013;13(3):340–51.
CAS
PubMed Central
PubMed
Google Scholar
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Ejso-Eur J Surg Onc. 2007;33(3):266–70.
Article
CAS
Google Scholar
Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ. Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma. Medicine. 2015;94(19):e751.
Article
CAS
PubMed Central
PubMed
Google Scholar
Luo GP, Xiao ZW, Long J, Liu ZQ, Liu L, Liu C, Xu J, Ni QN, Yu XJ. CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic Cancer. J Gastrointest Surg. 2013;17(12):2092–8.
Article
PubMed
Google Scholar
Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Oncotargets Ther. 2016;9:7459–67.
Article
CAS
Google Scholar
Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers. 2021;13(5):1071.
Article
CAS
PubMed Central
PubMed
Google Scholar
Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC, Wang XW. Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins. Carcinogenesis. 2007;28(7):1552–60.
Article
CAS
PubMed
Google Scholar
Yin LB, Xiao X, Georgikou C, Luo YQ, Liu L, Gladkich J, Gross W, Herr I. Sulforaphane Induces miR135b-5p and Its Target Gene, RASAL2, thereby Inhibiting the Progression of Pancreatic Cancer. Mol Ther-Oncolytics. 2019;14:74–81.
Article
CAS
PubMed Central
PubMed
Google Scholar
Berners-Price SJ. Activating Platinum Anticancer Complexes with Visible Light. Angew Chem Int Edit. 2011;50(4):804–5.
Article
CAS
Google Scholar
Mezencev R, Matyunina LV, Wagner GT, McDonald JF. Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther. 2016;23(12):446–53.
Article
CAS
PubMed Central
PubMed
Google Scholar
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
Hessmann E, Schneider G, Ellenrieder V, Siveke JT. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene. 2016;35(13):1609–18.
Article
CAS
PubMed
Google Scholar
Gabay M, Li YL, Felsher DW. MYC Activation Is a Hallmark of Cancer Initiation and Maintenance. Csh Perspect Med. 2014;4(6):a014241.
Google Scholar
Skoudy A, Hernandez-Munoz I, Navarro P. Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc. J Gastrointest Cancer. 2011;42(2):76–84.
Article
CAS
PubMed
Google Scholar
Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol. 2002;15(4):462–9.
Article
CAS
PubMed
Google Scholar
Birnbaum DJ, Adelaide J, Mamessier E, Finetti P, Lagarde A, Monges G, Viret F, Goncalves A, Turrini O, Delpero JR, et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer. 2011;50(6):456–65.
Article
CAS
PubMed
Google Scholar
Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, et al. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol Med. 2017;9(4):482–97.
Article
CAS
PubMed Central
PubMed
Google Scholar
Wirth M, Mahboobi S, Kramer OH, Schneider G. Concepts to Target MYC in Pancreatic Cancer. Mol Cancer Ther. 2016;15(8):1792–8.
Article
CAS
PubMed
Google Scholar